Listenly

What happens to pharma companies when procurement fails to manage drug development supplier costs?

Answered at 0:34 in Drug Development Is a Team Sport — And Procurement Has to Play. · Executive Edge Podcast

— questions searchable right now

What happens to pharma companies when procurement fails to manage drug development supplier costs?

If costs get out of hand, the company will lose money and might experience failures. In very risky early-stage investments, this can mean bankruptcy. This is why supporting supplier relationships and putting parameters around contracts to manage costs is critical to the success of the drug development process.

Dave Stowe on Executive Edge PodcastAll answers from this podcast →
Full answer and detailsRead the whole answer, key facts and every other question from this episode

In short

If costs get out of hand, the company will lose money and might experience failures.

Dave Stowe, Founder and Managing Partner at Adventus · Drug Development Is a Team Sport — And Procurement Has to Play. · Executive Edge Podcast · answer at 0:34

Key takeaways

  • If costs get out of hand, the company will lose money and might experience failures.

Quote to remember

“Somehow you've got to build those relationships. And I feel like when I've seen bad situations happen is people in the pharma space and the finance procurement do not extend it. They say, well, they should come and find me. And I'd say, no, it's the other way around. We need to go to them.”

— Dave Stowe

The full answer · about 1 min

If costs get out of hand, the company will lose money and might experience failures. In very risky early-stage investments, this can mean bankruptcy. This is why supporting supplier relationships and putting parameters around contracts to manage costs is critical to the success of the drug development process.

Key facts

  • Three main phases of clinical trials: Phase One, Two, and Three
  • Biotech spending scale progression: $20 million to $40 million to $80 million to $100 million to $200 million annually in drug development
  • Viagra development timeline: designed for heart treatment over 20 years ago before pivoting to different therapeutic use
  • Preclinical stage triggers: investigational new drug (IND) setup marks transition requiring more investor money and structured relationships
  • Patent protection: limited time period for pharmaceutical companies to recoup investments before drugs lose patent exclusivity and become subject to generic competition

People, companies and topics mentioned

AdventusContract Research Organizations (CROs)PwCOliver WymanHorizon TherapeuticsPurdue PharmaFDAInvestigational New Drug (IND)

More answers from this episode

 ·  All answers from Executive Edge Podcast →
—
—
0:00
0:00